---
annotation-target: blood.2022016945.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-20T12:40:40.256Z","updated":"2022-09-20T12:40:40.256Z","document":{"title":"blood.2022016945.pdf","link":[{"href":"urn:x-pdf:f1c7499232fab25fa3f2e36db7509581"},{"href":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf"}],"documentFingerprint":"f1c7499232fab25fa3f2e36db7509581"},"uri":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf","selector":[{"type":"TextPositionSelector","start":199,"end":237},{"type":"TextQuoteSelector","exact":"failure of anti-CD19CAR T-Cell Therapy","prefix":"ggressive B-Cell lymphoma after ","suffix":". A DESCAR-T analysis.Tracking n"}]}]}
>```
>%%
>*%%PREFIX%%ggressive B-Cell lymphoma after%%HIGHLIGHT%% ==failure of anti-CD19CAR T-Cell Therapy== %%POSTFIX%%. A DESCAR-T analysis.Tracking n*
>%%LINK%%[[#^i22j3j8p8|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^i22j3j8p8


>%%
>```annotation-json
>{"created":"2022-09-20T12:41:31.350Z","updated":"2022-09-20T12:41:31.350Z","document":{"title":"blood.2022016945.pdf","link":[{"href":"urn:x-pdf:f1c7499232fab25fa3f2e36db7509581"},{"href":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf"}],"documentFingerprint":"f1c7499232fab25fa3f2e36db7509581"},"uri":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf","selector":[{"type":"TextPositionSelector","start":9752,"end":9865},{"type":"TextQuoteSelector","exact":"Outcome of patients progressing/relapsing after CAR T-cells is poor, especially in case of relapse within 30 days","prefix":"4   Key points: -  Key point 1: ","suffix":"    -  Key point 2: Salvage immu"}]}]}
>```
>%%
>*%%PREFIX%%4   Key points: -  Key point 1:%%HIGHLIGHT%% ==Outcome of patients progressing/relapsing after CAR T-cells is poor, especially in case of relapse within 30 days== %%POSTFIX%%-  Key point 2: Salvage immu*
>%%LINK%%[[#^7p9btgdri67|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^7p9btgdri67


>%%
>```annotation-json
>{"created":"2022-09-20T12:41:36.230Z","updated":"2022-09-20T12:41:36.230Z","document":{"title":"blood.2022016945.pdf","link":[{"href":"urn:x-pdf:f1c7499232fab25fa3f2e36db7509581"},{"href":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf"}],"documentFingerprint":"f1c7499232fab25fa3f2e36db7509581"},"uri":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf","selector":[{"type":"TextPositionSelector","start":9885,"end":9986},{"type":"TextQuoteSelector","exact":"Salvage immunomodulatory treatment may offer better outcomes compared to standard immuno-chemotherapy","prefix":"thin 30 days    -  Key point 2: ","suffix":"     Downloaded from http://ashp"}]}]}
>```
>%%
>*%%PREFIX%%thin 30 days    -  Key point 2:%%HIGHLIGHT%% ==Salvage immunomodulatory treatment may offer better outcomes compared to standard immuno-chemotherapy== %%POSTFIX%%Downloaded from http://ashp*
>%%LINK%%[[#^58xa9sl45tl|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^58xa9sl45tl


>%%
>```annotation-json
>{"created":"2022-09-20T12:42:35.665Z","updated":"2022-09-20T12:42:35.665Z","document":{"title":"blood.2022016945.pdf","link":[{"href":"urn:x-pdf:f1c7499232fab25fa3f2e36db7509581"},{"href":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf"}],"documentFingerprint":"f1c7499232fab25fa3f2e36db7509581"},"uri":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf","selector":[{"type":"TextPositionSelector","start":10282,"end":10507},{"type":"TextQuoteSelector","exact":" However,  a  significant  number  of patients  experiences  failure.  Among  550  patients  registered  in  the  French  registry DESCAR-T, 238 (43.3%) experienced progression/relapse, with a median follow-up of 7.9 months. ","prefix":" aggressive  B-cell  lymphomas. ","suffix":"At registration, 57.0% of patien"}]}]}
>```
>%%
>*%%PREFIX%%aggressive  B-cell  lymphomas.%%HIGHLIGHT%% ==However,  a  significant  number  of patients  experiences  failure.  Among  550  patients  registered  in  the  French  registry DESCAR-T, 238 (43.3%) experienced progression/relapse, with a median follow-up of 7.9 months.== %%POSTFIX%%At registration, 57.0% of patien*
>%%LINK%%[[#^3s1ngwc22z|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^3s1ngwc22z


>%%
>```annotation-json
>{"created":"2022-09-20T12:43:02.120Z","updated":"2022-09-20T12:43:02.120Z","document":{"title":"blood.2022016945.pdf","link":[{"href":"urn:x-pdf:f1c7499232fab25fa3f2e36db7509581"},{"href":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf"}],"documentFingerprint":"f1c7499232fab25fa3f2e36db7509581"},"uri":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf","selector":[{"type":"TextPositionSelector","start":10751,"end":10863},{"type":"TextQuoteSelector","exact":"At  infusion,  66%  of  patients  presented  progressive  disease  and  38.9%  high  lactate dehydrogenase (LDH)","prefix":"7.8% received bridging therapy. ","suffix":". Failure after CAR T-cells occu"}]}]}
>```
>%%
>*%%PREFIX%%7.8% received bridging therapy.%%HIGHLIGHT%% ==At  infusion,  66%  of  patients  presented  progressive  disease  and  38.9%  high  lactate dehydrogenase (LDH)== %%POSTFIX%%. Failure after CAR T-cells occu*
>%%LINK%%[[#^5m063f82i2|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^5m063f82i2


>%%
>```annotation-json
>{"created":"2022-09-20T12:44:33.196Z","updated":"2022-09-20T12:44:33.196Z","document":{"title":"blood.2022016945.pdf","link":[{"href":"urn:x-pdf:f1c7499232fab25fa3f2e36db7509581"},{"href":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf"}],"documentFingerprint":"f1c7499232fab25fa3f2e36db7509581"},"uri":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf","selector":[{"type":"TextPositionSelector","start":11114,"end":11652},{"type":"TextQuoteSelector","exact":"After failure, 154 (64%) patients received salvage treatment: 38.3% had lenalidomide, 7.1%  bispecific  antibodies,  21.4%  targeted  treatment,  11%  radiotherapy,  and  20% immuno-chemotherapy with various regimens. Median progression-free survival was 2.8 months,  and  median  overall  survival  (OS)  was  5.2  months.  Median  OS  for  patients failing during D0-D30 versus after D30 was 1.7 vs 3.0 months respectively (p=0.0001). Overall, 47.9% of patients were alive at 6 months, but only 18.9% were alive after very early failure","prefix":"34.5%) had late (>D90) failure. ","suffix":". In multivariate analysis, pred"}]}]}
>```
>%%
>*%%PREFIX%%34.5%) had late (>D90) failure.%%HIGHLIGHT%% ==After failure, 154 (64%) patients received salvage treatment: 38.3% had lenalidomide, 7.1%  bispecific  antibodies,  21.4%  targeted  treatment,  11%  radiotherapy,  and  20% immuno-chemotherapy with various regimens. Median progression-free survival was 2.8 months,  and  median  overall  survival  (OS)  was  5.2  months.  Median  OS  for  patients failing during D0-D30 versus after D30 was 1.7 vs 3.0 months respectively (p=0.0001). Overall, 47.9% of patients were alive at 6 months, but only 18.9% were alive after very early failure== %%POSTFIX%%. In multivariate analysis, pred*
>%%LINK%%[[#^eroln4o42di|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^eroln4o42di


>%%
>```annotation-json
>{"created":"2022-09-20T12:45:28.391Z","updated":"2022-09-20T12:45:28.391Z","document":{"title":"blood.2022016945.pdf","link":[{"href":"urn:x-pdf:f1c7499232fab25fa3f2e36db7509581"},{"href":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf"}],"documentFingerprint":"f1c7499232fab25fa3f2e36db7509581"},"uri":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf","selector":[{"type":"TextPositionSelector","start":11793,"end":11961},{"type":"TextQuoteSelector","exact":"This multicentric analysis confirms the poor outcome of patients relapsing after CAR T-cells, highlighting the need for further strategies dedicated to this population.","prefix":"C-reactive protein at infusion. ","suffix":"   Downloaded from http://ashpub"}]}]}
>```
>%%
>*%%PREFIX%%C-reactive protein at infusion.%%HIGHLIGHT%% ==This multicentric analysis confirms the poor outcome of patients relapsing after CAR T-cells, highlighting the need for further strategies dedicated to this population.== %%POSTFIX%%Downloaded from http://ashpub*
>%%LINK%%[[#^98lsl9ksy7b|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^98lsl9ksy7b


>%%
>```annotation-json
>{"created":"2022-09-20T12:52:27.896Z","updated":"2022-09-20T12:52:27.896Z","document":{"title":"blood.2022016945.pdf","link":[{"href":"urn:x-pdf:f1c7499232fab25fa3f2e36db7509581"},{"href":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf"}],"documentFingerprint":"f1c7499232fab25fa3f2e36db7509581"},"uri":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220920/blood.2022016945.pdf","selector":[{"type":"TextPositionSelector","start":12334,"end":12932},{"type":"TextQuoteSelector","exact":"Valuable response rates have been observed both in pivotal clinical trials (JULIET, ZUMA 1 and TRANSCEND) and in real-world experience (CIMBTR,  CART  consortium  registry,  and  French,  Spanish  and  German  multi-centric studies).  Nonetheless,  failure  after  chimeric  antigen  receptor  (CAR)  T-cell  treatment remains a major issue, representing an unmet medical need. In the JULIET trial, nearly 60% of patients showed progression at 6 months after CAR T-cells infusion1. Similarly, the ZUMA 1 and TRANSCEND trials showed that approximately 50% of patients had relapsed  at  6  months2-4.","prefix":" lymphoma (R/R aggressive BCL). ","suffix":"  These  data  were  confirmed  "}]}]}
>```
>%%
>*%%PREFIX%%lymphoma (R/R aggressive BCL).%%HIGHLIGHT%% ==Valuable response rates have been observed both in pivotal clinical trials (JULIET, ZUMA 1 and TRANSCEND) and in real-world experience (CIMBTR,  CART  consortium  registry,  and  French,  Spanish  and  German  multi-centric studies).  Nonetheless,  failure  after  chimeric  antigen  receptor  (CAR)  T-cell  treatment remains a major issue, representing an unmet medical need. In the JULIET trial, nearly 60% of patients showed progression at 6 months after CAR T-cells infusion1. Similarly, the ZUMA 1 and TRANSCEND trials showed that approximately 50% of patients had relapsed  at  6  months2-4.== %%POSTFIX%%These  data  were  confirmed*
>%%LINK%%[[#^nya1px9u7cp|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^nya1px9u7cp
